…1 and T2 with no differences between DTG and TAF.Conclusions In PWH already on TAF, stopping TAF does not have an impact on lipid p…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 26 of 2459…Introduction Trichomonas vaginalis is estimated to be the most common non-viral sexually transmitt…
…9% male; 64.6% received fremanezumab, 24.8% erenumab, 10.6% and galcanezumab; 75.7% were on first-line therapy, 21.7% second-line and 2.7% t…
…eed for systematic studies beyond 48 weeks. Fenfluramine use in Aicardi syndrome, with no robust evidence base, was ineffective in our patient. …
…Objective To present updated integrated safety analyses of bimekizumab in patients with axial spondyloarthritis (axSpA) or psoriatic a…
…DXs of different histopathology, including, but not limited to, osteosarcoma, Ewing’s sarcoma, liposarcoma, myxofibrosarcoma, synovia sarcom…
…ion and potential as a therapeutic focus.Methods The potency of AVA-NP-695, a small-molecule ENPP1 inhibitor, was validated through enzyma…
…atide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from 1 December 2017 to 31 December 2023 were included. The as…
…ecommend screening patients at high risk of the condition using FIB4. In a recent national survey of >2000 Scottish adults, we found…
…owledging historically high prescribing of EFZ, we believe that Efavirenz is a previously unknown cause of DI-ALH. Awareness is important…
… ambulatory spinal anesthetics, with prilocaine, lidocaine, and mepivacaine as additional options depending on procedure length and patient…
…ore, accurately characterized by the authors like: ‘the highest Numeric Rating Scale (NRS) score recorded within the first 12 hours after the block …